Selling, General, and Administrative Costs: Galapagos NV vs Viridian Therapeutics, Inc.

A Comparative Analysis of SG&A Expenses: Galapagos NV vs. Viridian Therapeutics, Inc.

In the ever-evolving landscape of biotechnology, understanding the financial health of companies is crucial. Selling, General, and Administrative (SG&A) expenses are a key indicator of a company's operational efficiency. Over the past decade, Galapagos NV and Viridian Therapeutics, Inc. have shown contrasting trends in their SG&A expenses.

From 2014 to 2023, Galapagos NV's SG&A expenses surged by over 900%, peaking in 2022. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Viridian Therapeutics, Inc. maintained a more conservative growth, with expenses increasing by approximately 23% over the same period. Notably, in 2023, Viridian's SG&A expenses nearly matched those of Galapagos, indicating a strategic shift.

This analysis highlights the dynamic strategies of these biotech firms, offering insights into their operational priorities and market positioning.